Improve your knowledge in Cardio-Oncologythrough this program, where you will find the best teaching material with real case studies. Learn here about the latest advances in the specialty to be able to provide quality medical care"

Due to the growing importance of this clinical process, in recent years "multidisciplinary teams formed mainly by cardiologists and oncologists that make up the so-called Cardio-Oncology Units" have been developed.  

The objective of the Professional master’s degree in Cardio-Oncology is to offer up-to-date training in an area of current and future relevance from the clinical point of view, in which knowledge is advancing at breath-taking speed, focused on the training of professionals interested in the subject.

The Professional master’s degree will have two main axes around which all its modules will revolve: “Research and clinical applications”. All sections will be approached from the perspective of the most recent research findings. From the research point of view, both "basic and clinical research" lines will be addressed. The research background of the directors and co-directors of the Professional master’s degree will be reflected in all the modules. As this is a Professional master’s degree with a clinical application vocation, all modules will be introduced, and their content will be "applied to real clinical cases".

Cardiologists, oncologists, and hematologists with special interest in this field have, with this Professional master’s degree, the opportunity to complete and update their knowledge in Cardio-Oncology. The final objective of this Professional master’s degree will be for students to learn the "pathophysiological basis of the onset of CT, as well as how to detect and treat" it. Students will get to know, understand and apply the latest diagnostic techniques, and preventive and therapeutic measures specific to CT in oncology patients.

Emphasis will be placed on "solving complex clinical problems" such as the need for chemotherapy treatment in patients with severe heart disease or the occurrence of acute cardiovascular events in oncology patients undergoing chemotherapy treatment. It also offers a unique opportunity to learn about the latest advances in research in this field and aims to encourage students' interest in research.

Update your knowledge through the Cardio-Oncology program”

This Professional master’s degree in Cardio-Oncology contains the most complete and up-to-date scientific program on the market. The most important features of the program include:

• More than 75 clinical cases presented by experts in Cardio-Oncology
• The graphic, schematic, and eminently practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Diagnostic-therapeutic developments on assessment, diagnosis, and treatment in Cardio-Oncology 
• It contains practical exercises where the self-evaluation process can be carried out to improve learning
• Clinical and diagnostic imaging and testing iconography
• Algorithm-based interactive learning system for decision-making in the presented clinical situations
• With special emphasis on evidence-based medicine and research methodologies in Cardio-Oncology
• All this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Professional master’s degree may be the best investment you can make when selecting a refresher program, for two reasons: in addition to updating your knowledge in Cardio-Oncology, you will obtain a qualification from TECH"

The teaching staff includes professionals from the field of Cardio-Oncology, who bring their experience to this training program, as well as renowned specialists from leading scientific societies.

The multimedia content developed with the latest educational technology will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training program to train in real situations.

This program is designed around Problem Based Learning, whereby the medical must try to solve the different professional practice situations that arise throughout the course of the Professional master’s degree. For this purpose, the physician will be supported by an innovative interactive video system created by renowned and experienced experts in the field of Cardio-Oncology and other disciplines, with extensive teaching experience.

The Professional master’s degree provides training in simulated environments, which provides immersive learning designed to train professionals for real situations"

It includes clinical cases to bring the program's degree as close as possible to the reality of medical care"

The structure of the contents has been designed by a team of professionals from the best hospitals and universities in the country, who are aware of the relevance of up-to-date training to be able to intervene in the diagnosis and treatment of heart problems in oncology patients through the use of Cardio-Oncology, and are committed to quality teaching through new educational technologies.

This Professional master’s degree in Cardio-Oncology contains the most complete and up-to-date scientific program on the market”

Module 1. Epidemiology of Cancer

1.1. Epidemiological Significance of Cancer
1.2. Epidemiological Significance of Cardiotoxicity in Oncology
1.3. Epidemiological Significance of Cardiotoxicity in Hematology

Module 2. Oncologic Treatments with Cardiotoxic Effect

2.1. Definition of Cardiotoxicity. Affected Cardiac Chambers. Pathophysiological Mechanisms of Cardiotoxicity
2.2. Radiotherapy as a Cause of Cardiotoxicity

2.2.1. Evolution of Radiotherapy Equipment and Methods
2.2.2. Factors that Influence Radiation-Induced Cardiotoxicity
2.2.3. Acute Toxicity
2.2.4. Chronic Toxicity

2.3. Chemotherapy as a Cause of Cardiotoxicity

2.3.1. Anthracyclines
2.3.2. Antitubulin Drugs
2.3.3. Antimetabolites
2.3.4. Alkylating Agents and Other Drugs that Interact with DNA

2.4. Biological Agents as a Cause of Cardiotoxicity: Monoclonal Antibodies

2.4.1. Trastuzumab
2.4.2. Other Monoclonal Antibodies

2.5. Other Potentially Cardiotoxic Biological Agents

2.5.1. Cytokines
2.5.2. Interferons

2.6. Therapies Aimed at New Molecular Targets and Cardiotoxicity: Inhibitors of Cellular Kinases
2.7. Immune Checkpoint Inhibitors and Cardiotoxicity
2.8. Other Potentially Cardiotoxic Oncologic Treatments

2.8.1. Histone Deacetylase Inhibitors
2.8.2. Oral Antiangiogenics
2.8.3. Differentiation and/or Apoptosis Inducers
2.8.4. Hormonal Agents

Module 3. Comprehensive Assessment of the Risk of Cardiotoxicity Development

3.1. Individual Susceptibility to Cardiotoxicity: Genetic Factors
3.2. Individual Susceptibility to Cardiotoxicity: Non-Genetic Factors

3.2.1. Cardiovascular Risk Factors
3.2.2. Comorbidities
3.2.3. Combination of Oncologic Treatments

3.3. Cardiological Assessment before Treatment in Patients without Known Heart Disease

3.3.1. Clinical Assessment
3.3.2. Complementary Tests

3.4. Cardiological Assessment before Treatment in Patients with Known Heart Disease

3.4.1. Clinical Assessment
3.4.2. Complementary Tests

3.5. Monitoring during Treatment of Patients Subjected to Cardiotoxic Treatments

3.5.1. Clinical Assessment
3.5.2. Complementary Tests

Module 4. Early Detection of Cardiotoxicity

4.1. Circulating Biomarkers: Troponins
4.2. Circulating Biomarkers: Natriuretic Peptides
4.3. Other Circulating Biomarkers for Early Detection of Cardiotoxicity
4.4. Echocardiography
4.5. Cardiovascular Magnetic Resonance Imaging
4.6. Computerised Axial Tomography

Module 5. Myocardial Toxicity

5.1. Incidence and Clinical Relevance
5.2. Pathophysiology of Ventricular Dysfunction and Heart Failure in the Context of Cardiotoxicity
5.3. Drugs Implicated in the Development of Ventricular Dysfunction and Heart Failure

5.3.1. Anthracyclines
5.3.2. Other Chemotherapy Drugs
5.3.3. Biological Agents: Monoclonal Antibodies
5.3.4. Therapies Aimed at New Molecular Targets: Inhibitors of Cellular Kinases
5.3.5. Proteosome Inhibitors

5.4. Radiotherapy and Heart Failure
5.5. Methods for Diagnosing Myocardial Involvement

5.5.1. Electrocardiogram
5.5.2. Echocardiography
5.5.3. Other Non-Invasive Imaging Techniques

5.6. Treatment Strategies

5.6.1. Treatment of Acute Heart Failure
5.6.2. Chronic Treatment of Patients with Ventricular Dysfunction

5.7. Presymptomatic Myocardial Involvement

5.7.1. Management of Patients with Elevated Circulating Biomarkers during Oncologic Treatment
5.7.2. Management of Patients with Preclinical Impairment of Ventricular Function during Oncologic Treatment

5.8. Monitoring Strategy during Treatment with Drugs Capable of Causing Myocardial Toxicity.

5.8.1. Anthracyclines
5.8.2. Biological Agents: Monoclonal Antibodies
5.8.3. Therapies Aimed at New Molecular Targets: Inhibitors of Cellular Kinases
5.8.4. Immune Checkpoint Inhibitors

Module 6. Ischemic Heart Disease and Cardiotoxicity

6.1. Incidence of Ischemic Heart Disease in Oncology Patients
6.2. Identifying Patients at High Risk of Coronary Artery Disease
6.3. Pathophysiology of Ischemic Heart Disease in the Context of Oncologic Treatment
6.4. Pharmacologic Oncologic Therapies that are Associated with Ischemic Heart Disease

6.4.1. Fluoropyrimidine
6.4.2. Vascular Endothelial Growth Factor Inhibitors
6.4.3. Others (Cisplatin)

6.5. Diagnostic Methods for Coronary Artery Disease Related to Cardiotoxic Drugs

6.5.1. Electrocardiogram
6.5.2. Functional Tests
6.5.3. Non-Invasive Imaging Tests
6.5.4. Invasive Imaging Tests

6.6. Acute Coronary Syndrome in the Context of Oncologic Treatment
6.7. Monitoring and Treatment Strategy in the Patient with Coronary Ischemia
6.8. Thoracic Radiotherapy and Ischemic Heart Disease

6.8.1. Incidence and Pathophysiology of Radiation-Induced Coronary Artery Disease
6.8.2. Risk Factors for the Development of Ischemic Heart Disease in Radiotherapy Patients
6.8.3. Clinical Assessment and Diagnostic Methods of Coronary Heart Disease in Radiotherapy Patients
6.8.4. Treatment Options in Coronary Artery Disease Associated with Radiotherapy

6.9. Management of Chronic Ischemic Patients Receiving Oncologic Treatment

Module 7. Arrhythmias and Cardiotoxicity

7.1. Incidence and Pathophysiology of Cardiac Arrhythmias Related to Oncologic Treatments
7.2. QT Interval Prolongation: Causative Drugs and Associated Risk Factors
7.3. QT Interval Prolongation: Diagnostic Criteria and Risk Stratification of Ventricular Arrhythmias
7.4. QT Interval Prolongation: Prevention Strategies and Implications on the Continuity of Specific Treatment
7.5. Atrial Fibrillation: Incidence, Risk Factors, and Clinical Presentation
7.6. Atrial Fibrillation: Oncologic Treatments Involved in its Development
7.7. Atrial Fibrillation: Anticoagulant Treatment

7.7.1. Thrombotic and Hemorrhagic Risk Assessment
7.7.2. Anticoagulation with Heparin
7.7.3. Anticoagulation with Dicoumarinics
7.7.4. Direct-Acting Anticoagulants

7.8. Treatment Strategy in Atrial Fibrillation: Rate Control versus Rhythm Control
7.9. Bradyarrhythmias Associated with Oncologic Treatment

7.9.1. Sinus Dysfunction
7.9.2. Atrioventricular Block
7.9.3. Therapeutic Implications

Module 8. Valvular and Pericardial Involvement Related to Cardiotoxicity

8.1. Oncologic Treatments that May Lead to the Development of Valvulopathies

8.1.1. Pharmacological Treatments
8.1.2. Thoracic Radiotherapy

8.2. Management of Chronic Valvular Patients Receiving Oncologic Treatment

8.2.1. Mitral Valve Disease
8.2.2. Aortic Valve Disease
8.2.3. Valve Prosthesis

8.3. Pharmacological Treatments that May Lead to the Development of Pericardial Disease

8.3.1. Incidence and Physiopathology
8.3.2. Clinical Presentation and Diagnosis
8.3.3. Approach to Pericardial Effusion Secondary to Treatment

8.4. Thoracic Radiotherapy and Pericardial Disease

8.4.1. Acute Pericarditis
8.4.2. Chronic Pericarditis

8.5. Assessing Patients with Metastatic Pericardial Involvement

Module 9. Arterial Hypertension as a Result of Oncologic Treatments

9.1. Clinical Relevance of Hypertension in Oncology Patients
9.2. Arterial Hypertension Associated with Antiangiogenic Drugs

9.2.1. Incidence
9.2.2. Pathophysiology
9.2.3. Diagnosis

9.3. Other Treatments Associated with the Development of Arterial Hypertension.
9.4. Treatment of Arterial Hypertension Related to Oncologic Treatment
9.5. Monitoring Strategy

Module 10. Venous Thromboembolic Disease and Other Vascular Complications in the Oncology Patient

10.1. Venous Thromboembolic Disease in the Oncologic Patient: Clinical Significance

10.1.1. Incidence
10.1.2. Pathophysiology
10.1.3. Risk Factors

10.2. Antineoplastic Treatments Associated with Increased Risk of Thromboembolic Disease

10.2.1. Chemotherapy and Antiangiogenic Drugs
10.2.2. Hormone Therapy

10.3. Prevention of Cancer-Related Venous Thromboembolic Disease

10.3.1. Prevention Strategy in Outpatients with Active Oncology Treatment. Thrombotic Risk Scales
10.3.2. Prevention Strategy in Hospitalized Patients
10.3.3. Periosurgery Prevention Strategy

10.4. Venous Thromboembolic Disease Related to the Use of Central Venous Catheters

10.4.1. Incidence
10.4.2. Clinical Presentation
10.4.3. Diagnostic Methods
10.4.4. Treatment and Monitoring
10.4.5. Prevention

10.5. Forms of Presentation and Diagnosis of Cancer-Associated Thromboembolic Disease

10.5.1. Deep Vein Thrombosis
10.5.2. Pulmonary Embolism

10.6. Treatment of Cancer-Associated Thromboembolic Disease

10.6.1. Initial Treatment
10.6.2. Extended Treatment

10.7. Management of Thromboembolic Disease in Special Situations

10.7.1. Brain Tumors
10.7.2. Obesity
10.7.3. Renal Insufficiency
10.7.4. Thrombopenia

10.8. Primary Prevention of Cardiovascular Disease in Cancer Patients

10.8.1. Incidence and Risk Factors
10.8.2. Implicated Drugs
10.8.3. Clinical Diagnosis and Treatment

10.9. Cerebrovascular Disease

10.9.1. Incidence and Risk Factors
10.9.2. Implicated Treatments
10.9.3. Clinical Diagnosis and Treatment

10.10. Pulmonary Hypertension

10.10.1. Implicated Drugs. Pathophysiology
10.10.2. Clinical Diagnosis
10.10.3. Treatment and Monitoring

Module 11. Therapies with Cardioprotective Effects

11.1. Identification and Control of Cardiotoxicity Risk

11.1.1. Treatment of Traditional Risk Factors
11.1.2. Treatment of Comorbidities

11.2. Strategies to Limit Oncologic Drug-Related Cardiotoxicity

11.2.1. Anthracyclines
11.2.2. Monoclonal Antibodies. HER2 Inhibitors
11.2.3. Cell Kinase Inhibitors

11.3. Strategies to Limit Cardiotoxicity Related to Thoracic Radiotherapy
11.4. Role of Beta-Blockers in Cardioprotection
11.5. Role of Angiotensin Receptor Inhibitors and Antagonists in Cardioprotection
11.6. Other Interventions with a Possible Cardioprotective Effect

Module 12. Long-Term Monitoring Programs for Patients Who Have Received Cardiotoxic Therapies

12.1. Risk of Late Cardiotoxicity Secondary to Oncological Drugs
12.2. Monitoring Protocol for the Detection of Late Cardiotoxicity
12.3. Risk of Late Cardiotoxicity Secondary to Thoracic Radiotherapy
12.4. Monitoring Protocol for Detecting Late Radiation-Induced Toxicity

Module 13. Complex Clinical Situations in the Context of Cardiotoxicity

13.1. Patient with Complex Cardiovascular Disease Requiring Oncologic Treatment.
13.2. Patient with Oncologic Disease Presenting with an Acute Ischemic Event.
13.3. Pediatric Patients in Need of Potentially Cardiotoxic Oncology Treatment.
13.4. Geriatric Patients in need of Oncologic Treatment.
13.5. Oncology Patients Requiring Anticoagulation or Anti-Aggregation.
13.6. Oncology Patients who Exhibit Arrhythmias and Require Implantable Devices (Pacemakers, Defibrillators).

Module 14. The Future of Cardio-Oncology: Most Relevant Lines of Research

14.1. Basic Research.
14.2. Clinical Research.
14.3. Gaps in Evidence and Future Research.

Module 15. Multidisciplinary Cardio-Oncology Units

15.1. Objectives of the Cardio-Oncology Units.

15.1.1. Care Objectives.
15.1.2. Research Objectives.
15.1.3. Teaching and Dissemination Objectives.

15.2. Components of Cardio-Oncology Equipment.

15.2.1. Coordination between the In-Hospital and Out-of-Hospital Environment.
15.2.2. Coordination between Different Healthcare Professionals.

A unique, key, and decisive training experience to boost your professional development”